Lessons Learned from First Ten Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug Resistant Bacterial Infections at a Single Center in the US

  01 September 2020

Due to increasing multidrug resistant (MDR) infections there is an interest is assessing the use of bacteriophage therapy (BT) as an antibiotic alternative. After the first successful case of intravenous BT to treat a systemic MDR infection at our institution in 2017, the Center for Innovative Phage Applications and Therapeutics (IPATH) was created at the University of California, San Diego in June 2018.

We demonstrate the safety and feasibility of intravenous BT for a variety of infections and discuss practical considerations that will be critical for informing future clinical trials.

Author(s): Saima Aslam, Elizabeth Lampley, Darcy Wooten, Maile Karris, Constance Benson, Steffanie Strathdee, Robert T Schooley
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition





Technology Database

Display your AMR Technology, Product and Service

 

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

 

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!